Last reviewed · How we verify

NCT04240587: INTAC

Intranasal Neurostimulation for the Treatment of Neurosensory Abnormalities in CL Wearers (INTAC)

Withdrawn NA Last updated 11 November 2021
What this trial tests

NA trial testing TrueTear™ intranasal neurostimulator (ITN) in Contact Allergy. Withdrawn.

Timeline
23 March 2020
Primary endpoint
3 November 2021
3 November 2021

Quick facts

Lead sponsorTufts Medical Center
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Start date23 March 2020
Primary completion3 November 2021
Estimated completion3 November 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Tufts Medical Center

Who can join

21 and older, any sex, with Contact Allergy or Neuropathic Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To find out if the use of an intranasal tear neurostimulator (ITN), may be useful in decreasing the pain symptoms felt by patients who experience contact lens discomfort.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of TrueTear™ intranasal neurostimulator (ITN)

Trials testing the same drug.

Other Tufts Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04240587.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing